NexImmune, Inc.
DelistedCIK 1538210fmd_02FYAW0ZKGM89T82DF04V5TBBEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2024, 18 periods
Latest annual · FY2021
Millions- Total revenues
- 0
- Operating income
- (33)
- Net income
- (32)
- Free cash flow
- (31)
Latest quarter · Q2 FY2024
Millions- Operating income
- (4)
- Net income
- (2)
- Free cash flow
- (2)
NexImmune, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Operating income | -$33 million | -$63.1 million | 10-K 2024-04-16 · proof | |
| Net income | -$32.3 million | -$62.5 million | 10-K 2024-04-16 · proof | |
| Cash from operating activities | -$31.4 million | -$51.2 million | 10-K 2024-04-16 · proof | |
| Free cash flow | -$31.5 million | -$52.4 million | 10-K 2024-04-16 · proof | |
| Total assets | $8.6 million | $43.1 million | -80% | 10-K 2024-04-16 · proof |
| Total liabilities | $5.1 million | $10.8 million | -52.7% | 10-K 2024-04-16 · proof |
| Cash and cash equivalents | $3.2 million | $34.6 million | -90.8% | 10-K 2024-04-16 · proof |
- What was NexImmune, Inc.'s operating income in fiscal 2023?
- NexImmune, Inc. reported operating income of -$33 million for fiscal 2023 (the year ended Dec 31, 2023), against -$63.1 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What was NexImmune, Inc.'s net income in fiscal 2023?
- NexImmune, Inc. reported net income of -$32.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$62.5 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What was NexImmune, Inc.'s cash from operating activities in fiscal 2023?
- NexImmune, Inc. reported cash from operating activities of -$31.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$51.2 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What was NexImmune, Inc.'s free cash flow in fiscal 2023?
- NexImmune, Inc. reported free cash flow of -$31.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$52.4 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What are NexImmune, Inc.'s total assets?
- As of Dec 31, 2023, NexImmune, Inc. reported total assets of $8.6 million, against $43.1 million a year earlier (-80%). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What are NexImmune, Inc.'s total liabilities?
- As of Dec 31, 2023, NexImmune, Inc. reported total liabilities of $5.1 million, against $10.8 million a year earlier (-52.7%). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
- What are NexImmune, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, NexImmune, Inc. reported cash and cash equivalents of $3.2 million, against $34.6 million a year earlier (-90.8%). Source: the 10-K filed with the SEC on Apr 16, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1538210&period_type=annual&limit=5"Information only, not investment advice.